BHVN - Goldman Sachs raises obesity drug market estimate to $130B
2024-05-30 11:22:06 ET
More on Eli Lilly, Novo, etc.
- Novo Nordisk: The Market Is Right, Don't Fight Against It
- Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study
- Novo Nordisk: Considerable Growth Beyond Ozempic
- Lilly's Retevmo gains approval for children as young as two with thyroid cancer
- Ro provides supply tracking feature for Lilly, Novo Nordisk weight loss drugs